Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Wall Street To Follow Europe And China Gains

Fri, 10th Jul 2015 11:07

LONDON (Alliance News) - UK shares are higher Friday midday as Wall Street is expected to take a positive lead from European stocks, boosted by optimism for a deal between Greece and its creditors, and another positive session for Chinese stock markets.

The FTSE 100 index is up 1.3% at 6,667.00, with only three stocks in the red. The FTSE 250 is up 0.9% at 17,448.15, and the AIM All-Share is up 0.4% at 747.45.

European stocks are once again outperforming London, with the CAC 40 in Paris up 2.9% and the DAX 30 in Frankfurt up 2.1%.

Meanwhile, US futures point to a higher open, with the Dow Jones Industrial Average pointed up 1.0%, the S&P 500 up 1.1% and the Nasdaq 100 up 1.2%.

The most important event in the US will be later in the afternoon, as US Federal Reserve Chair Janet Yellen is due to speak about the economic outlook in Cleveland, Ohio, at 1730 BST. Before that, US wholesale inventories are expected 1500 BST.

"With tensions high over the possible approval of a Greek bailout over the weekend, Yellen will probably try not to signal any change to her economic outlook," says CMC Markets analyst Jasper Lawler. "She will receive questions though, so there is some scope for something unexpected."

Outside the US, attention is on Greece. In a move seen as the Mediterranean country's final bid to keep the euro, the government placed a cash-for-reforms proposal before creditors late Thursday. It comprises spending cuts and tax hikes in exchange for a third bailout, acceptance of which will pave the way for further negotiations between both sides.

Eurogroup President Jeroen Dijsselbloem received the proposal from Greece, his spokesman Michel Reijns said in a Twitter message. Eurozone finance ministers will meet on Saturday in Brussels to review the Greek request.

That was meant to be followed by a summit attended by 28 national leaders of the EU on Sunday to reach a final agreement. However an EU official said Friday morning that no EU summit will be held on Sunday if the Eurogroup of finance ministers agrees with the Greek offer on Saturday.

Prime Minister Alexis Tsipras' request for at least EUR53.5 billion in bailout funds for the next three years will be presented in the Greek parliament for approval on Friday. The new list of reforms makes concessions to creditors' demands in key areas including VAT and pension reform, according to a copy of the document seen by dpa.

The Greek program is "serious, credible" and shows "a determination to remain in the euro area", French President Francois Hollande said in a message on Twitter. Nothing is decided yet, everything can be done, he added.

However, IG Markets analyst Alastair McCaig says "there still remains the tricky issue of the Greek parliament approving this proposal, which was by and large rejected in a national referendum less than a week ago," he writes. "Assuming that the Greeks can all agree with themselves we would then need to see the creditors approve this proposal over the weekend. Of course the more cynical market observer will be asking themselves how reliable a Greek promise is anyway."

London and European stocks also are being supported by a second consecutive session of strong gains by Chinese stock markets following successive declines. The Hang Seng closed up 2.1% in Hong Kong and the Shanghai Composite rose 4.5%.

The gains came as China's securities regulator banned senior management and investors who own stakes in businesses exceeding 5% from selling their shares for next six months, and China's central bank injected CNY35 billion into the money market by buying bonds.

The recovery in Chinese equities also lifted metal prices, after they had fallen to multi-year lows earlier in the week.

"This quick recovery [in metal prices] supports our view of fundamentals having taken a backseat as markets were predominantly driven by concerns about Chinese growth and uncertainties related to the equity market correction," says Carsten Menke, commodities research analyst at Julius Baer.

"It remains to be seen whether the Chinese economy will escape unscathed from the equity market correction or whether it will weigh on consumption, e.g. purchases of jewellery and cars," the analyst adds.

The recovery has supported shares in London-listed miners, with BHP Billiton up 2.0%, Glencore up 1.2% and Anglo American up 1.0%.

Elsewhere on the corporate front, InterContinental Hotels Group is up 3.0% after it has agreed to sell its stake in the InterContinental Hong Kong to Supreme Key for USD938 million. Nomura says the value is at the top end of the broker's appraised value of USD783-940 million, and Numis says this looks like a "very acceptable price" and the achieved price is some USD150 million above its expectation.

IHG will retain a 37-year management contract for the hotel, with three ten-year extension rights. It expects to be paid management fees of around USD8 million a year, which will increase after the refurbishment is completed.

International Consolidated Airlines Group is up 2.6%, after Irish budget carrier Ryanair Holdings said its board has voted unanimously to accept IAG's offer for its stake in Aer Lingus Group, removing the final barrier in the way of IAG's takeover bid and paving the way for the protracted transaction to go through. Ryanair shares trade up 2.7%, and Aer Lingus is up 2.4%.

In the AIM All-Share, Aurasian Minerals shares are up 18%. The South-East Asian focused miner said it has appointed Peter Mullens as its new chief executive, and that Mullens has agreed to subscribe to new Aurasian shares alongside a new non-executive director to raise GBP207,500 for the company. The company said Mullens has over 30 years of experience in mining and exploration geology and is currently a director of Royal Road Minerals, which is listed on the Toronto Stock Exchange. Previously, he had held roles at Lydian International and Aquiline Resources.

Reneuron Group is up 16% at 5.66p. The stem-cell company posted a widened pretax loss for its 2015 financial year due to rises in research and development and administrative costs, but said it has placed 1.37 billion shares at 5 pence per share to raise GBP68.4 million to back its therapeutic programmes. Shares in the company closed at 4.875 pence on Thursday.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
15 Apr 2014 12:23

ReNeuron leases building for relocation of business

AIM-listed ReNeuron has signed a deal with the Welsh government to lease a landmark building at Pencoed Technology Park, near Cardiff in South Wales. The stem cell therapy company explained that it will build a new state-of-the-art facility at Pencoed, to which it will relocate the business next ye

Read more
15 Apr 2014 10:01

ReNeuron Leases New Research & Development Facility With Welsh Government

LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC said Tuesday that it had signed an agreement with the Welsh Government to lease a new research and development facility at the Pencoed Technology Park near Cardiff, South Wales. ReNeuron expects to begin to relocate its o

Read more
15 Apr 2014 07:50

UK MORNING BRIEFING: Aggreko Leads After Mixed Results

LONDON (Alliance News) - Aggreko is leading the FTSE 100 in early trading Tuesday after the temporary power company said it has seen mixed results in its first quarter, with strong underlying revenue growth in two of its three regions being impacted by adverse currency movements as previously exp

Read more
27 Mar 2014 13:48

UK MIDDAY BRIEFING: Regulators Confirm UK Energy Market Review

LONDON (Alliance News) - UK regulators have now confirmed they will investigate whether the country's major energy companies are preventing effective competition in the market, a decision that prompted British Gas parent Centrica to warn that the review could delay crucial investments in new i

Read more
27 Mar 2014 13:01

UK WINNERS & LOSERS: Babcock, Tullow Oil Lead Blue-Chip Fallers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.

-------

FTSE 100 - WINNERS

Old Mutual, up 0.5%. The group has agreed to sell Skandia Germany and S

Read more
27 Mar 2014 11:13

ReNeuron Gets Approvals To Begin Two New Trials Using Stem Cell Product

LONDON (Alliance News) - ReNeuron Group PLC said Thursday that it has received final regulatory and ethical approvals to begin two new clinical trials using its CTXcyro stem cell product. The company will begin a Phase II clinical trial of its ReN001 investigational therapy in stroke disabi

Read more
14 Mar 2014 13:04

ReNeuron Eyes New UK Government Scheme Encouraging Novel Therapies

LONDON (Alliance News) - ReNeuron Group PLC Friday said it will look at whether the UK government's plan to launch a scheme to encourage the take up of novel therapies could be applied to its own therapeutic candidates. The scheme, called the Early Access to Medicines Scheme, is looking to

Read more
11 Mar 2014 12:48

US foundation funds ReNeuron stem cell therapy

A US-based charity has agreed to provide funding and access to clinical expertise for ReNeuron's retinal stem cell therapy candidate for a degenerative eye disease. Shares in ReNeuron rose 8.8% to 3.54p on the news. The Foundation for Fighting Blindess has agreed to provide further funding toward

Read more
11 Mar 2014 11:27

ReNeuron Retinal Stem Cell System Wins FFB Support

LONDON (Alliance News) - ReNeuron Group PLC said Tuesday its retinal stem cell therapy candidate is to receive support from a retinal research funding foundation. ReNeuron said its ReN003 retinal stem cell therapy candidate for the treatment of retinis pigmentosa is set to receive support

Read more
21 Jan 2014 10:04

ReNeuron Sees Positive Data For Stem Cells In Retinal Degeneration Test

LONDON (Alliance News) - ReNeuron Group PLC said Tuesday that a paper detailing the efficiency of its human retinal stem cells in a test model of retinal degeneration had been published in the Journal of Biological Chemistry. The test showed that ReNeuron's cells protected visual function w

Read more
21 Jan 2014 08:19

UK MORNING BRIEFING: Shares Higher; Unilever, SABMiller As Expected

LONDON (Alliance News) - UK shares have opened higher Tuesday, as Unilever and SABMiller have released results and trading statements in line with expectations.

Peel Hunt has issued ratings on the property sector, cutting Great Portland Est

Read more
13 Sep 2013 09:02

ReNeuron Moving All Therapeutic Programmes To Phase II Trials In Next 3 Years

Read more
22 Jul 2013 10:50

ReNeuron announces capital increase, funds to enter capital structure

Lifesciences group ReNeuron has announced that it has successfully raised 33m pounds in fresh funding to finance its research into stem-cell development, although it had to offer a small discount for the new equity. Significantly, three new investment funds are to enter its shareholder register with

Read more
28 May 2013 10:39

ReNeuron jumps on stem cell study results

Shares in AIM-listed stem cell business ReNeuron Group rose on Tuesday morning after the group unveiled details of progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. The group said that the primary aim of the study was to test the safety and toler

Read more
26 Mar 2013 09:45

ReNeuron Group to begin stem cell treatment of critical limb ischaemia

ReNeuron Group has received regulatory approval to begin the first phase of a clinical trial in the UK for the company's ReN009 stem cell therapy treatment for critical limb ischaemia. Critical limb ischaemia, a condition which leads to blood vessel blockage in limbs such as toes and can lead to am

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account